Chengdu Institute of Biological Products: Subsidiary's Component Diphtheria, Pertussis, Tetanus, and Hib Quadrivalent Vaccine Receives Clinical Trial Approval.

Chengdu Institute of Biological Products announces that its subsidiary, Chengdu Green Bamboo, has received approval from the National Medical Products Administration to conduct clinical trials for a combination pertussis-Hib quadrivalent vaccine. This vaccine is designed to prevent infections caused by Bordetella pertussis, Corynebacterium diphtheriae, Clostridium tetani, and Haemophilus influenzae type b. The vaccine can reduce the number of injections required, increasing the compliance of vaccination. Currently, there is no approved combination pertussis-Hib quadrivalent vaccine in China, indicating a promising market outlook. If the project progresses smoothly, it will synergize with the company's phase III clinical trials for a combination pertussis vaccine, further strengthening the company's position in the market.